© The Rockefeller University Press, 0022-1007/1999/8/311/ $5.00
The Journal of Experimental Medicine, Volume 190, Number 3, August 2, 1999 311-322
A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells
Umadevi V. Wesleya,
Anthony P. Albinoa,
Shakuntala Tiwaria, and
Alan N. Houghtona
a From the Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division, Weill Graduate School of Medical Sciences of Cornell University, New York 10021
Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.212-794-4352212-639-7595
a-houghton{at}ski.mskcc.org
 |
Abstract
|
|---|
Dipeptidyl peptidase IV (DPPIV) is a cell surface peptidase expressed by normal melanocytes, epithelial cells, and other cells. Malignant cells, including melanomas and carcinomas, frequently lose or alter DPPIV cell surface expression. Loss of DPPIV expression occurs during melanoma progression at a stage where transformed melanocytes become independent of exogenous growth factors for survival. Tetracycline-inducible expression vectors were constructed to express DPPIV in human melanoma cells. Reexpressing DPPIV in melanoma cells at or below levels expressed by normal melanocytes induced a profound change in phenotype that was characteristic of normal melanocytes. DPPIV expression led to a loss of tumorigenicity, anchorage-independent growth, a reversal in a block in differentiation, and an acquired dependence on exogenous growth factors for cell survival. Suppression of tumorigenicity and reversal of a block in differentiation were dependent on serine protease activity, assessed using mutant DPPIV molecules containing serine
alanine substitutions. Surprisingly, dependence on exogenous growth factors was not dependent on serine protease activity. Reexpression of either wild-type or mutant DPPIV rescued expression of a second putative cell surface serine peptidase, fibroblast activation protein 
, which can form a heterodimer with DPPIV. This observation suggests that rescue of fibroblast activation protein may play a role in regulating growth of melanocytic cells. These results support the view that downregulation of DPPIV is an important early event in the pathogenesis of melanoma.
Key Words: melanoma • fibroblast activating protein • serine protease • tumorigenicity • differentiation
© 1999 The Rockefeller University Press
Dipeptidyl peptidase IV (DPPIV)1 is a cell surface peptidase that is expressed on epithelia, melanocytes, and T cells 123. It is a type II membrane glycoprotein that has multiple properties, including serine protease activity and the ability to bind adenosine deaminase and extracellular matrix components 234. Because it binds to adenosine deaminase, DPPIV has also been called adenosine deaminase binding protein or adenosine deaminase complexing protein 45. DPPIV expression on T cells has been designated CD26 3.
It has been recognized for several decades that expression of DPPIV can be extinguished or altered on cancer cells 678. Loss or alteration of membrane expression of DPPIV has been reported in prostate, colorectal, lung, and hepatocellular carcinomas and melanomas 2678910111213. DPPIV expression during malignant transformation has been best characterized in melanocytic cells. DPPIV is expressed in vitro and in vivo by normal melanocytes but not by melanoma, the malignant counterpart 213. Previous studies have shown that expression of DPPIV is lost as melanocytes are transformed into melanoma cells 21314. Loss of DPPIV expression probably occurs at an early stage of melanoma progression as melanocytes transform into melanoma cells 2. Specifically, DPPIV is expressed by cutaneous melanocytes and common nevi but is not detected in vivo or in vitro on cells from primary or metastatic melanomas. In an in vitro system that sequentially transformed melanocytes in defined steps, loss of DPPIV expression occurred concomitantly with the emergence of growth factor independence 1314.
Despite these correlative observations both in vivo and in vitro, a role for DPPIV in regulating the malignant phenotype has not been shown. We report that reexpression of DPPIV in human melanoma cells at levels comparable to those found in normal melanocytes produced profound phenotypic changes. These included abrogation of tumor-igenicity, reemergence of requirements for exogenous growth factors to maintain cell survival, and removal of a block in cell differentiation. Using a point mutation in the active serine protease domain of DPPIV, we observed that serine peptidase activity was required for most effects but not for cell survival. Reexpression of DPPIV rescued expression of a second putative surface peptidase, fibroblast activation protein (FAP) 15, suggesting that expression of this second molecule contributes to effects on cell survival in malignant cells.
|
Materials and Methods
|
|---|
Wild-Type and Mutant Plasmid Constructs.
Tetracycline-inducible expression vectors pUHG16-3 and pUHD172-1neo were provided by Hermann Bujard (Zentrum für Molekulare Biologie der Universität Heidelberg, Heidelberg, Germany) 16. The plasmid pUHG16-3 has a cytomegalovirus minimal promoter fused to a tetracycline operator (teto). Transcription is activated by the reverse tet repressor in the presence of tetracycline or doxycycline (dox). pUHD172-1neo has a neomycin resistance gene and reverse tetracycline-controlled transactivator 16. Full length cDNA (2.3 kb) of human DPPIV was amplified by PCR and subcloned into the XbaI site of pUHG16-3 to create pDPPIV. The DNA sequence was identical to the human DPPIV sequences, available from EMBL/GenBank/DDBJ under accession number M74777. The orientation of the insert was confirmed by DNA sequencing and restriction enzyme digests. Mutant DPPIV (pmuDPPIV, producing amino acid substitution of alanine for serine at codon 630, was constructed using the QuickChangeTM Site-Directed Mutagenesis Kit (Stratagene, Inc.). The oligonucleotide primers used for site-directed mutagenesis were 5'-GCA ATT TGG GGC TGG GCA TAT GGA GGG TAC-3' and 5'-GTA CCC TCC ATA TGC CCA GCC CCA AAT TGC-3'. Mutants were identified by DNA sequencing.
Establishment of Human Melanoma Cells Expressing DPPIV.
Human melanoma cells and melanocytes were established and cultured as described 171819. Human melanoma cell lines MEL-22a, SK-MEL-28, and SK-MEL-29 were cotransfected with plasmid pUHD 172-1neo and empty vector pUHG16-3, pDPPIV, or pmuDPPIV. Lipofectamine reagent was used for transfections as described by the manufacturer (GIBCO BRL Life Technologies).
Immunofluorescence Microscopy and Flow Cytometry.
Cells were grown on chamber slides (Nunc, Inc.) and then stained with mAb S27 (4 µg/ml) against DPPIV or mAb TA99 against gp75TRP-1 and incubated with FITC-conjugated rabbit anti–mouse IgG (DAKO Corp.). Stained cells were viewed with a Nikon Optiphot microscope. Flow cytometry was performed using FACScanTM (Becton Dickinson). Cells were stained with S27 mAb or F19 mAb (anti-FAP) 20 and FITC-conjugated rabbit anti–mouse IgG.
Immunoprecipitation and Western Blot Analysis.
For immunoprecipitation assays 21, cells were cultured in medium containing [35S]methionine (NEN Dupont) for 18 h, and cell lysates were precipitated with anti-DPPIV mAb S27. Western blot analysis was performed as described 21 using rabbit PEP7H antibody against human tyrosinase (a gift of Vincent Hearing, National Institutes of Health [NIH], Bethesda, MD).
Dipeptidyl Peptidase Enzyme Activity, In Situ Apoptotic Cell Detection by TdT-mediated dUTP-Biotin Nick-End Labeling Assay, Cell Cycle Analysis, Anchorage-independent Studies, and Growth Curves.
DPPIV peptidase activity was measured by colorimetric assay 22. In brief, cells expressing DPPIV in the presence (2 µg/ml for 2–4 d) or absence of dox were suspended in lysis buffer containing 0.5% CHAPS (3-[3-cholamidopropyl]dimethyl-ammonio-1-propanesulfonate). Untransfected and vector-transfected cells were used as controls. 30 µl of cell lysates was incubated with 10 µl of 10 mM substrate, Gly-Pro p-nitroanilide (Sigma Chemical Co.), at 37°C for 30 min. Reactions were stopped with 250 µl of 10% TCA, and the supernatants were mixed with 250 µl of 0.1% NaNO2 and incubated at room temperature for 3 min followed by addition of 250 µl 0.5% ammonium sulfamate. At the end of a 2-min incubation, 500 µl of 0.05% N-(1-naphthyl)ethylenediamine was added, and p-nitroaniline release was measured at 540 nm. Peptidase activities were standardized based on protein concentration and also on cell number. Protein concentrations were measured by the Bradford assay using the BioRad DC protein assay kit. Specific activities were expressed as picomoles per microgram protein per minute.
For apoptosis assays, cells were grown in plain RPMI medium without serum for 3, 8, or 15 d. TdT-mediated dUTP-biotin nick-end labeling (TUNEL) assay was performed using the APOPTAG kit (Oncor, Inc.). Percent apoptosis was calculated by FACScanTM (Becton Dickinson). Evidence of apoptosis and percent of cells in each phase of the cell cycle was analyzed by CellFIT and PC-LYSISTM software (Becton Dickinson).
Growth curves were determined as described 18. In brief, cells were plated at a density of 104 cells per well in triplicate in 24-well plates. Every 3 d, cultures were refed with fresh media. Cells were trypsinized daily for 10–12 d and stained with trypan blue, and viable cells were counted. Time of doubling was determined from a least squares regression fit of cell number versus time during the logarithmic growth phase.
Colony formation was performed in soft agar. In brief, the top layer, consisting of 5,000 viable cells suspended in 0.3% agarose and RPMI 1640 with 20% FCS, was overlaid on a 1% agarose layer in 35-mm culture plates. 14 d after seeding, colonies 
200 µm in diameter were counted under a light microscope. The data are presented as the mean of triplicate plates.
Tumor Growth In Vivo.
Nude mice (nu/nu, BALB/c) were injected subcutaneously with 3 x 106 cells (either MEL-22a or SK-MEL-29) expressing mutant or wild-type DPPIV and control cells. Five to six animals were used for each group. The tumors were measured every 2–3 d along the greatest diameter. All mouse experiments were performed under protocols approved by the Institutional Animal Care and Utilization Committee of Memorial Sloan-Kettering Cancer Center according to NIH animal care guidelines.
|
Results
|
|---|
Establishment and Characterization of Melanoma Cells Expressing DPPIV.
To define a possible functional role of DPPIV in melanocytic cells, we established melanoma cells that expressed DPPIV in an inducible manner using tetracycline-inducible vectors. Three human melanoma cell lines, MEL-22a, SK-MEL-28, and SK-MEL-29, derived from metastatic lesions of different patients, were selected for study. These melanoma cell lines are representative of more than 150 melanoma cell lines that we have tested that do not express detectable DPPIV glycoprotein (reference 2 and our unpublished data). In addition, the growth and differentiation of these three melanoma lines have been well characterized 1718. These cell lines represent different stages of melanocyte/melanoma differentiation 17. They are either completely nonpigmented with a phenotype that corresponds to an immature stage of melanocyte differentiation (MEL-22a) or minimally pigmented with a phenotype of an intermediate stage of melanocyte differentiation (SK-MEL-28 and SK-MEL-29; reference 17 and 18; Table ).
Because we had trouble isolating stable transfectants expressing DPPIV using constitutive vectors, we used an inducible vector system. Melanoma cells were cotransfected with a neomycin-resistant regulator plasmid and tetracycline-inducible vector carrying: (a) the full length wild-type (wt)DPPIV cDNA, (b) a mutant (mut)DPPIV having minimal serine protease activity (substitution of alanine for serine at codon 630 altering the catalytic domain), or (c) a control empty vector 16. Multiple clones that expressed each cDNA construct were isolated for each cell line (Table and Table ). Transfected clones expressing empty vector and mutDPPIV were always relatively easy to derive, and at least three clones were established for each melanoma cell line. Transfected clones expressing wtDPPIV were more difficult to establish, suggesting that DPPIV expression affected cell survival or growth. Despite this difficulty, seven different clones expressing low, medium, and high levels of DPPIV were selected from MEL-22a transfectants, and two clones each were isolated for SK-MEL-28 and SK-MEL-29.
DPPIV expression was assessed by three methods: (a) immunofluorescence staining, (b) immunoprecipitation from metabolically labeled cells, and (c) enzymatic activity. Fig. 1 shows DPPIV expression in representative clones of MEL-22a transfectants, with or without induction by dox. DPPIV cell surface expression was substantially induced by dox (Fig. 1 A). Melanoma cells transfected with wtDPPIV and mutDPPIV expressed the expected 110–120-kD glycoprotein, showing that both the wild-type and mutant polypeptides were processed and expressed appropriately (Fig. 1 B). Furthermore, these results showed that mutDPPIV was stable and expressed at levels comparable to those of wtDPPI. A weak 110-kD band was detected in parental cells and cells transfected with empty vector upon long exposure of autoradiographs (Fig. 1 B), suggesting that melanoma cells can express very low levels of endogenous DPPIV.
View larger version (178K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Expression of DPPIV in transfected melanoma cells. (A) Immunofluorescence microscopy showing expression of DPPIV. MEL-22a cells were cultured in the presence or absence of dox (2 µg/ml) for 48 h and stained with S27 mAb against DPPIV. Groups include untransfected MEL-22a cells (panel 1) and control vector–transfected cells (panel 2); cells transfected with wtDPPIV and grown in the absence of dox (panel 3) or induced with dox for 48 h (panel 4); cells transfected with mutDPPIV grown in the absence of dox (panel 5) or induced with dox for 48 h (panel 6). Original magnification 400. (B) Immunoprecipitation analysis of DPPIV expression in MEL-22a cells transfected with wt- or mutDPPIV. Cells were labeled with [35S]methionine for 18 h, lysed with 1% NP-40, immunoprecipitated with mAb S27 against DPPIV, analyzed by 9% SDS-PAGE, and visualized by autoradiography. The first and second lanes (from left) are untransfected MEL-22a and vector-transfected MEL-22a controls, respectively. The third and fourth lanes are two separate clones of transfected MEL-22a cells expressing either high (hi) or intermediate (med) levels of wtDPPIV when grown in the presence of dox. The fifth lane is MEL-22a cells transfected with mutDPPIV grown in the presence of dox. The sixth lane shows wtDPPIVhi-transfected MEL-22a clone grown in the absence of dox. Arrow, 110–120 kD band of DPPIV. –, not induced or +, induced with dox. (C) DPPIV activity in MEL-22a clones transfected with wtDPPIV, mutDPPIV, or control vector and in cultured normal foreskin melanocytes. Three different clones of MEL-22a cells transfected with wtDPPIV were analyzed expressing low (wtDPPIVlow), intermediate (wtDPPIVmed), and high (wtDPPIVhi) levels of enzyme activity. Open bars (–dox), enzyme activities in absence of dox; hatched bars (+dox), enzyme activity after induction with dox. Results shown are mean values ± 1 SD of triplicates.
| |
Transfected clones and parental melanoma cells were assessed for DPPIV enzymatic activity (Table and Fig. 1 C). Parental and vector control–transfected cells expressed 
30 pM/min/µg protein of DPPIV activity, which we believe represents very low endogenous DPPIV activity. In the absence of dox, DPPIV activity in DPPIV-transfected melanoma cells was 60 pM/min/µg protein. Peptidase activity of melanoma cells induced to express high levels of wtDPPIV in the presence of dox was 220–310 pM/min/µg protein (Table and Fig. 1 C). This level was comparable to that of melanocytes (300–350 pM/min/µg protein; range from three distinct assays; Fig. 1 C). Despite high expression of mutDPPIV protein (Fig. 1a and Fig. b), melanoma cells expressing mutDPPIV exhibited low levels of enzyme activity even in the presence of dox (60 pM/min/µg protein; Table and Fig. 1 C). Transfected MEL-22a clones were isolated that expressed high (hi), medium (med), and low DPPIV activity for more detailed studies to compare phenotype and level of DPPIV expression (Fig. 1b and Fig. c).
In summary, levels of DPPIV expression were consistent across the three assays, showing that steady-state level of protein expression corresponded to wtDPPIV enzymatic activity. As expected, there was low DPPIV enzyme activity in cells expressing mutDPPIV. Results of DPPIV activity in transfected melanoma lines SK-MEL-28 and SK-MEL-29 showed levels similar to those of MEL-22a (Table ). These results showed that: (a) the maximum level of DPPIV activity in transfected melanoma cells did not exceed levels expressed by cultured normal melanocytes (either normalized to protein concentration or when calculated on a per-cell basis), (b) dox induced DPPIV expression fivefold or more, and (c) mutDPPIV expressed minimal or no enzyme activity.
Inhibition of Tumorigenicity by Expression of DPPIV.
Tumorigenicity of melanoma cells expressing wtDPPIV or mutDPPIV was compared with that of control melanoma cells. Nude mice were injected subcutaneously with transfected and control MEL-22a or SK-MEL-29 melanoma cells (parental SK-MEL-28 melanoma cells do not form tumors in immune-compromised mice). Parental and control vector melanoma cells formed progressive tumors in all mice. Fig. 2a and Fig. b shows results from two different experiments for MEL-22a, and Fig. 2 C shows results for SK-MEL-29. Tumorigenicity was essentially ablated in MEL-22a cells when DPPIV was induced to levels expressed by normal melanocytes (wtDPPIVhi). Mice showed no progression of tumors over 100 d (Fig. 2a and Fig. b), although viable tumor cells remained after 100 d (data not shown). Similar results were observed with SK-MEL-29 expressing wtDPPIV (Fig. 2 C). Tumor growth was also reduced in melanoma cells expressing medium levels of DPPIV, although not as profoundly as for high levels of DPPIV (Fig. 2a and Fig. c). Transfected MEL-22a melanoma cells expressing low levels of DPPIV, either in the absence of induction of DPPIV (wtDPPIVhi [–dox], Fig. 2 A) or constitutively (DPPIVlow [+dox], Fig. 2 B), showed slightly reduced tumor growth, perhaps due to either low levels of DPPIV activity or recruitment of FAP, which forms a heterodimer with DPPIV (as discussed below). Melanoma cells expressing high levels of mutDPPIV formed tumors at variable rates, with some mice showing inhibition of tumor growth (note error bars in Fig. 2a and Fig. c for mutDPPIV). These results were consistent with a require-ment of DPPIV serine peptidase activity for complete inhibition of tumorigenicity. However, inconsistent inhibition of tumorigenicity in melanoma cells expressing mutDPPIV suggested that some effects of DPPIV on in vivo tumor growth were possibly independent of DPPIV serine peptidase activity.
Inhibition of Anchorage-independent Growth by Expression of DPPIV.
Another characteristic of malignant cells is anchorage-independent growth. Expression of DPPIV led to a marked decrease in the ability of MEL-22a melanoma cells to grow in soft agar. DPPIV expression inhibited colony-forming ability by 
75% in MEL-22a cells, with little inhibition of MEL-22a cells expressing mutDPPIV compared with parental and vector control cells (Fig. 3). Thus, serine peptidase activity was required to decrease anchorage-independent growth.
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Anchorage-independent growth in soft agar. MEL-22a cells described in Fig. 2 A were cultured in the absence (–) or presence (+) of dox for 48 h, and 5,000 viable cells were plated in agar in triplicate as described in Materials and Methods. Results are mean number of colonies ± 1 SD at 14 d. Results are pooled from two separate experiments.
| |
Phenotypic Changes of Melanoma Cells Expressing DPPIV.
Marked morphological changes were observed in melanoma cells expressing wtDPPIV (Fig. 4 and Table ). Parental MEL-22a melanoma cells and cells transfected with control vector or mutDPPIV were a disorganized array of epithelioid, polygonal, and short bipolar spindle-shaped cells and grew in piled colonies without any apparent organization (Fig. 4 A). Cells expressing medium or high levels of wtDPPIV were consistently long bipolar spindle shaped, with organized growth behavior and sheet-like appearance, suggesting organization by cell–cell contact (Fig. 4 A). SK-MEL-28 and SK-MEL-29 cells also changed morphology from the long spindle shape of parental-, control vector–, and mutDPPIV-transfected cells to a more mature polydendritic shape of cells expressing wtDPPIV (Table ). The polydendritic shape is characteristic of well-differentiated melanoma cells 1718.
We have previously shown that MEL-22a cells have a block in differentiation associated with a nonpigmented, immature melanocytic phenotype 18. Five MEL-22a clones expressing medium and high levels of DPPIV were pigmented when grown to confluence (Fig. 4 B and Table ). Three clones expressing mutDPPIV had no pigment. None of the six clones with control vector nor parental cells were pigmented (Fig. 4 B and Table ). Differentiation of melanocytic cells is characterized not only by appearance of pigmentation but by expression of melanosome membrane glycoproteins involved in melanin metabolism. The best characterized glycoproteins are members of the tyrosinase family, including tyrosinase and tyrosinase-related proteins (TRP). Expression of wtDPPIV, but not mutDPPIV, correlated with a markedly increased expression of human tyrosinase (Fig. 4 C). Expression of wtDPPIV (but not mutDPPIV) was also associated with de novo expression of the brown locus protein, gp75TRP-1 23, measured by indirect immunofluorescence staining (data not shown). Expression of gp75TRP-1 and upregulation of tyrosinase protein occur at a later stage in melanocyte differentiation, confirming that the tyrosinase low/gp75TRP-1–negative MEL-22a had differentiated. Induction of pigmentation associated with expression of DPPIV was also observed in the two other melanoma cell lines, SK-MEL-28 and -29 (Table ). These observations show that DPPIV expression is associated with a relief of the block in differentiation of melanoma cells.
Growth Characteristics of Melanoma Cells Expressing DPPIV.
Expression of DPPIV did not affect growth of MEL-22a cells during the logarithmic growth phase. The doubling time of cells expressing high wtDPPIV, mutDPPIV, and control vectors was 36–38 h and was exactly the same as for parental MEL-22a in culture media containing serum (36 h). However, melanoma cells expressing medium and high levels of wtDPPIV had a much longer lag period after plating before they entered the logarithmic growth phase (4–5 d) compared with parental cells and melanoma cells expressing mutDPPIV and control vectors (1–2 d). Also, growth of wtDPPIV cells was inhibited when cells reached a confluent state, whereas parental melanoma cells and cells expressing mutDPPIV and control vector continued to grow and pile up after reaching confluency (Fig. 4 A). Thus, the total cell number of wtDPPIV cells was decreased by 40% compared with control melanoma cells or mutDPPIV cells on days 10–14 after plating. This was due to the delay before entering logarithmic growth but also perhaps to inhibited growth upon reaching confluency. Thus, wtDPPIV expression did not affect log growth of MEL-22a cells but did slow entry into the rapid growth phase and appeared to induce some level of growth inhibition at cell confluency. The difficulty in initiating growth might explain in part the difficulty in establishing transfected clones of melanoma cells expressing wtDPPIV.
Apoptosis and Block of Cell Cycle in Serum-Free Conditions Induced by DPPIV Expression.
Transformed cells are typically released from dependence on exogenous growth factors for survival during tumor progression 24. This characteristic applies to melanoma cells, which have been shown to survive and grow in serum-free culture medium without addition of exogenous growth factors, whereas normal melanocytes die over 7–14 d when serum is withdrawn 2526. We had previously shown that loss of DPPIV expression was associated with acquisition of growth factor independence during in vitro transformation of melanocytes 1413. This observation demonstrated a correlation between DPPIV expression and a requirement for exogenous growth factors for survival. We investigated this possible link by growing transfected and parental melanoma cells in serum-free conditions.
WtDPPIV, mutDPPIV, and control MEL-22a cells were serum starved with or without induction of DPPIV by dox. Parental and vector control cells grew in serum-free media with only low levels of detectable apoptotic cell death (2–3% of cells showed DNA fragmentation by TUNEL assay over 15 d) (Table ). A minor population of transfected melanoma cells not induced for wtDPPIV cells demonstrated cell death in serum-free conditions (21% of cells at 15 d; (Table ). However, cells induced to express either wtDPPIV or mutDPPIV with dox showed a marked, progressive loss of cell viability; the proportion of apoptotic cells was 15–18% at day 3, 45–53% at day 8, and 62–78% at day 15 (Table ). Similar results were observed with SK-MEL-29 cells. Only 8% of control vector–transfected cells were apoptotic 8 d after serum withdrawal compared with 52% of cells expressing wtDPPIV.
The same set of cells was analyzed for cell cycle progression in serum-free conditions (Fig. 5). wtDPPIVhi expression induced a cell cycle arrest at the G0/G1 phase, with 62–76% of the cells present in the G0/G1 stage by day 8 compared with only 5–12% of control vector and parental cells in the G0/G1 (range of percentages from duplicates of two experiments). Interestingly, cell cycle arrest at the G0/G1 stage was detected in 32% of cells expressing mutDPPIV, intermediate between wtDPPIV and melanoma cells not expressing DPPIV. These results with mutDPPIV suggest either that some other function than serine protease activity of DPPIV is involved in apoptosis and cell cycle arrest induced by serum withdrawal or that DPPIV interacts with other molecules that mediate survival and cell cycle effects.
View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Cell cycle analysis of melanoma cells expressing DPPIV and FAP. Expression of both wt- and mutDPPIV in MEL-22a cells was associated with changes in cell cycle. Parental MEL-22a cells and cells transfected with control vector, mutDPPIV, and wtDPPIV were assessed for cell cycle progression after 8 d of culture in serum-free media. Number of cells at each stage of the cell cycle were measured by flow cytometry (first peak was G0/G1, the intervening trough was S phase, and the second peak represented cells in G2/M) and analyzed by CellFIT and PC-LYSISTM software.
| |
DPPIV Rescues Expression of FAP.
FAP is a potential cell surface serine protease that is coexpressed with DPPIV by melanocytes. Loss of FAP expression occurs concomitantly with loss of DPPIV expression during in vitro transformation of melanocytes, and expression is also lost in primary and metastatic melanoma cell lines 1415. DPPIV and FAP can form heterodimers in addition to homodimers formed by DPPIV 15. Reexpression of either wt- or mutDPPIV by MEL-22a melanoma cells induced the cell surface expression of FAP (Fig. 6). The relative level of surface expression of FAP corresponded to the level of DPPIV expression, irrespective of wild-type or mutant forms. Thus, DPPIV rescued surface expression of FAP.
|
Discussion
|
|---|
Cell surface proteases are generally thought to participate in malignant transformation and cancer progression by facilitating invasion and metastasis. Inhibition of surface proteases can block tumor progression, and aberrant expression can facilitate tumorigenesis 27. However, cell surface proteases may also have the opposite effect, suppressing the malignant phenotype 27. How cell surface proteases play a role in suppressing the malignant phenotype of human cancer without interacting with the extracellular matrix is not well characterized.
Our results show that loss of DPPIV expression is directly implicated in suppressing the malignant phenotype of melanoma cells. A crucial question arising from these studies is how a cell surface peptidase might have such pleiotropic effects on the malignant phenotype of melanoma cells, reversing tumorigenicity, affecting the differentiation program, and changing decisions about survival without exogenous growth factors. DPPIV has several functions, including serine peptidase activity, binding to extracellular matrix components, and complexing adenosine deaminase 3. Thus, each of these particular functions, presumably handled by different domains of the protein, could contribute to suppression of the malignant phenotype. Serinealanine mutation did not suppress tumorigenicity or anchorage-independent growth, nor did it reverse the block in differentiation, showing that serine peptidase activity is required for these phenotypic changes. The different contributions of other domains and functions of DPPIV and recruitment of FAP is yet uncertain. Biochemical and enzymatic studies may give clues to their potential functions.
Reexpression of DPPIV led to apoptotic cell death upon serum withdrawal and cell cycle arrest. Unexpectedly, apoptosis was also observed in cells expressing mutDPPIV, which suggests that the rescue of FAP as a heterodimer with DPPIV could explain at least part of these proapoptotic effects. At this point, we have no data to support this notion other than this correlative observation. However, consistent with this view, a paralogue of FAP is induced during tadpole tail resorption, which is essentially a massive program of cell death 28, suggesting that a proapoptotic role of FAP might be conserved throughout vertebrate evolution. FAP contains a potential serine protease site, but the functions of FAP protein, including peptidase activity, are not well characterized. It will be important to determine whether FAP has serine protease activity and if this function might be important for proapoptotic effects induced by expression of DPPIV. It will also be important to identify downstream components that are involved in decisions about melanoma cell survival and how DPPIV and FAP participate in these decisions. Pathways for cell survival in melanocytes are not well understood. However, bcl-2 is probably a central mediator of resistance to apoptotic death in melanocytic cells 2930, and one speculation is that DPPIV expression might ultimately intersect with bcl-2.
DPPIV expression may play a crucial role in checking cell growth of normal melanocytes. This idea is supported by our observations that loss of DPPIV correlates with growth factor–independent proliferation of melanoma cells 1314, as well as the experiments described above. One explanation is that DPPIV degrades growth factors required for survival of melanocytic cells. As our experiments were performed in strict serum-free conditions, the most likely source of growth factors is autocrine factors secreted by melanoma cells. In prostate cancer, autocrine neuropeptides such as bombesin and endothelin-1 can stimulate the growth of prostate carcinoma cells, and these growth factors are inactivated by the cell surface metallopeptidase, neutral endopeptidase 24.11 31. Chemokines are potential substrates for DPPIV, including RANTES (regulated on activation, normal T cell expressed and secreted), stromal cell–derived factors 1 and 1β, IP-10 (IFN-
–inducible protein 10), monocyte chemotactic proteins 1, -2, and -3, and GCP-2 (granulocyte chemotactic protein 2) 3233343536. In addition, regulatory peptides, including glucagon-like peptide 1 and 2, neuropeptide Y, and peptide YY are DPPIV substrates 3738. It is uncertain whether chemokines or regulatory peptides could be involved in maintaining the malignant phenotype of melanoma or whether other substrates of DPPIV are involved. It will be important to identify substrates of DPPIV that are made as autocrine factors by melanoma cells.
|
Acknowledgments
|
|---|
We are indebted to Mark Morrison for help in cloning the human DPPIV gene, Lawrence Lai for assistance in flow cytometry, and Yoichi Moroi, Teresa Ramirez, Cedric S. Wesley, and Polly Gregor for helpful advice.
This work was supported in part by Swim Across America, the Way Foundation, and the Louis and Anne Abrons Foundation.
Submitted: 5 March 1999
Revised: 21 May 1999
Accepted: 7 June 1999
1used in this paper: dox, doxycycline; DPPIV, dipeptidyl peptidase IV; FAP, fibroblast activating protein ; TRP, tyrosinase-related protein; TUNEL, TdT-mediated dUTP-biotin nick-end labeling
A.P. Albino's present address is American Health Foundation, 1 Dana Rd., Valhalla, NY 10595.
|
References
|
|---|
Schrader W.P. & Stacy A.R.. Purification and subunit structure of adenosine deaminase from human kidney, J. Biol. Chem., 252, 1977, 6409–6415.[Free Full Text]
Houghton A.N., Albino A., Cordon-Cardo C., Davis L.J. & Eisinger M.. Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation, J. Exp. Med., 167, 1988, 197–212.[Abstract/Free Full Text]
Morimoto C. & Schlossman S.. The structure and function of CD26 in the T-cell immune response, Immunol. Rev., 61, 1998, 55–70.
Schrader W.P., West C.A., Miczek A.D. & Norton E.K.. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction, J. Biol. Chem., 265, 1990, 19312–19318.[Abstract/Free Full Text]
Schrader W.P. & Pollara B.. Localization of an adenosine deaminase-binding protein in human kidney, J. Lab. Clin. Med., 92, 1978, 656–662.[Medline]
Fogh, J. 1975. Human Tumor Cells In Vitro. Plenum Press, New York. 183 pp.
Herbschleb-Voogt E., Ten Kate J. & Meera Khan P.. Adenosine deaminase complexing proteina transformation sensitive protein with potentials of a cancer marker, Anticancer Res., 3, 1983, 95–100.[Medline]
Ten Kate J., Dinjens N.M.W., Meera Khan P. & Bosman F.D.. Adenosine deaminase complexing protein in cancer studies, Anticancer Res., 6, 1986, 983–988.[Medline]
Bogenrieder T., Finstad C.L., Freeman R.H., Papandreou C.N., Scher H.I., Albino A.P., Reuter V.E. & Nanus D.M.. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue, Prostate., 33, 1997, 225–232.[Medline]
Dinjens W.N., Ten Kate J., Kirch J.A., Tanke H.J., Van der Linden E.P., Van den Ingh H.F., Van Steenbrugge G.J., Meera Khan P. & Bosman F.T.. Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas, J. Pathol., 160, 1990, 195–201.[Medline]
Ten Kate J., van den Ingh H.F., Khan P.M. & Bosman F.T.. Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma, Int. J. Cancer., 37, 1986, 479–485.[Medline]
Sakamoto J., Watanabe T., Teramukai S., Akiyama S., Morimoto T., Takagi H., Nakazato H., Ueda R. & Takahashi T.. Distribution of adenosine deaminase binding protein in normal and malignant tissues of the gastrointestinal tract studied by monoclonal antibodies, J. Surg. Oncol., 52, 1993, 124–143.[Medline]
Morrison M.E., Vijayasaradhi S., Engelstein D., Albino A.P. & Houghton A.N.. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase, J. Exp. Med., 177, 1993, 1135–1143.[Abstract/Free Full Text]
Albino A.P., Sozi Z., Nanus D.M., Jhanwar C.S. & Houghton A.N.. Malignant transformation of human melanocytesinduction of a complete melanoma phenotype and genotype, Oncogene., 7, 1992, 2315–2321.[Medline]
Rettig W.J., Garin-Chesa P., Healey J.H., Su S.L., Ozer H.L., Schwab M., Albino A.P. & Old L.J.. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin, Cancer Res, 53, 1993, 3327–3335.[Abstract/Free Full Text]
Gosse M., Freundlieb S., Bender G., Muller G., Hillen W. & Bujard H.. Transcriptional activation by tetracyclines in mammalian cells, Science., 268, 1995, 1766–1769.[Abstract/Free Full Text]
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G. & Old L.J.. Surface antigens of melanocytes and melanomasmarkers of melanocyte differentiation and melanoma subsets, J. Exp. Med., 156, 1982, 1755–1766.[Abstract/Free Full Text]
Houghton A.N., Real F.X., Davis L.J., Cordon-Cardo C. & Old L.J.. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells, J. Exp. Med., 164, 1987, 812–829.
Eisinger M. & Marko O.. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin, Proc. Natl. Acad. Sci. USA., 79, 1982, 2018–2022.[Abstract/Free Full Text]
Garin-Chesa P., Old L.J. & Rettig W.J.. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers, Proc. Natl. Acad. Sci. USA., 87, 1990, 7235–7239.[Abstract/Free Full Text]
Xu Y., Vijayasaradhi S. & Houghton A.N.. The cytoplasmic tail of the mouse brown locus product determines intracellular stability and export from the endoplasmic reticulum, J. Invest. Dermatol., 110, 1998, 324–331.[Medline]
Kojima K., Hama T., Kato T. & Nagatsu T.. Rapid chromatographic purification of dipeptidyl peptidase IV in human submaxillary gland, J. Chromatogr, 189, 1980, 233–240.[Medline]
Thomson T.M., Real F.X., Murakami S., Cordon-Cardo C., Old L.J. & Houghton A.N.. Differentiation antigens of melanocytes and melanomaanalysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies, J. Invest. Dermatol., 4, 1988, 459–466.
Sporn M.B. & Todaro G.J.. Autocrine secretion and malignant transformation of cells, N. Engl. J. Med, 303, 1980, 878–880.[Medline]
Rodeck U., Herlyn M., Menssen H.D., Furlanetto R.W. & Koprowski H.. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors, Int. J. Cancer., 40, 1987, 687–690.[Medline]
Real F.X., Fliegel B. & Houghton A.N.. Surface antigens of human melanoma cells cultured in serum free mediuminduction of expression of major histocompatibility complex class II antigen, Cancer Res., 48, 1988, 686–693.[Abstract/Free Full Text]
Werb Z.. ECM and cell surface proteolysisregulating cellular ecology, Cell., 191, 1997, 439–442.
Brown D.D., Wang Z., Furlow J.D., Kanamori A., Schwartzman R.A., Remo B.F. & Pinder A.. The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis, Proc. Natl. Acad. Sci. USA., 93, 1996, 1924–1929.[Abstract/Free Full Text]
Yamamura K., Kamada S.I., Nakagawa K., Ichihashi M. & Tsujimoto Y.. Accelerated disappearance of melanocytes in bcl-2-deficient mice, Cancer Res., 56, 1996, 3546–3550.[Abstract/Free Full Text]
Ramsay J.A., From L. & Kahn H.J.. bcl-2 protein expression in melanocytic neoplasms of the skin, Mod. Pathol., 8, 1995, 150–154.[Medline]
Papandreou C.N., Usmani B., Geng Y., Bogenrieder T., Freeman R., Wilk S., Finstad C.L., Reuter V.E., Powell C.T. & Scheinberg D.. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression, Nat. Med., 4, 1998, 50–57.[Medline]
Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., Boykins R., Unsworth E. & Norcross M.A.. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage, J. Exp. Med., 186, 1997, 1865–1872.[Abstract/Free Full Text]
Van Coillie E., Proost P., Van Aelst I., Struyf S., Polfliet M., De Meester I., Harvey D.J., Van Damme J. & Opdenakker G.. Functional comparison of two human monocyte chemotactic protein-2 isoforms. Role of the aminoterminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV, Biochemistry., 37, 1998, 12672–12680.[Medline]
Proost P., De Meester I., Schols D., Struyf S., Lambeir A.M., Wuyts A., Opdenakker G., De Clercq E., Scharpe S. & Van Damme J.. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection, J. Biol. Chem., 273, 1998, 7222–7227.[Abstract/Free Full Text]
Proost P., Struyf S., Schols D., Durinx C., Wuyts A., Lenaerts J.P., De Clercq E., De Meester I. & Van Damme J.. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1, FEBS Lett., 432, 1998, 73–76.[Medline]
Shioda T., Kato H., Ohnishi Y., Tashiro K., Ikegawa M., Nakayama E.E., Hu H., Kato A., Sakai Y. & Liu H.. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1 (SDF-1) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage, Proc. Natl. Acad. Sci. USA., 95, 1998, 6331–6336.[Abstract/Free Full Text]
Drucker D.J., Shi Q., Crivici A., Sumner-Smith M., Tavares W., Hill M., DeForest L., Cooper S. & Brubaker P.L.. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV, Nat. Biotechnol., 15, 1997, 673–677.[Medline]
Medeiros M.S. & Turner A.J.. Post-secretory processing of regulatory peptidesthe pancreatic polypeptide family as a model example, Biochimie., 76, 1994, 283–287.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Top
Abstract
Materials and Methods
